#Pioneering Advances in Pediatric AML Insights from Phase 2 Trial of SLS009 and Beyond

Sellas doses first paediatric subject with AML in Phase II trial of SLS009

Sellas Life Sciences has dosed the first paediatric subject with AML in its Phase II trial of SLS009 (tambiciclib).The post Sellas doses first paediatric subject with AML in Phase II trial of SLS009 appeared first on Clinical Trials Arena.

#Pioneering Advances in Pediatric AML Insights from Phase 2 Trial of SLS009 and Beyond

Acute Myeloid Leukemia (AML) is a severe hematologic malignancy impacting both adults and children. The pediatric variant of AML tends to have unique genetic features and treatment challenges. Recent progress in targeted therapies and personalized medicine offers hope for better outcomes, particularly for patients who do not respond to standard treatments. Key developments have arisen from the work of SELLAS Life Sciences, particularly involving…